Stay updated on Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.

Latest updates to the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page
- ChecktodayChange DetectedThe site’s revision identifier was updated from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoChange DetectedThe study page displays details for a completed Phase 2 trial of pembrolizumab plus paclitaxel for hypermutated, hormone receptor-positive metastatic breast cancer, including enrollment, study design, eligibility, and outcome measures.SummaryDifference44%

- Check14 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide NIH notice announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434, and the site revision advances from v3.7.1 to v3.7.2. The study record remains behind a 403 error.SummaryDifference1%

- Check42 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe 403 Forbidden error page (and the Home link) was removed, and the page now shows the standard study details layout with navigation.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.